Failure of Short Telomere Study not accurate portrayal of results - why the negative spin?
In the original primary analysis of PFS, imetelstat given as maintenance therapy appeared to prolong
PFS in patients with advanced NSCLC whose tumors have short telomeres, as measured by a
retrospective qPCR assay.
Results for Telo-FISH, a prospective assay, show a trend toward increased PFS benefit in the short
Mature OS analyses suggest a survival benefit in patients with both short telomeres and mediumlong
telomeres. These data are not consistent with the hypothesis that clinical benefit from
telomerase inhibition is potentially greater in patients with tumors possessing short telomeres.
The impact of these findings on the development of imetelstat in solid tumors with short telomeres
is being evaluated.
Help me with the above - it sounds as though the results were actually better than expected - in other words OS increased for short and medium teliomeres. Please feel free to correct me if I'm misreading this.
It baffles me as to why Scarlett_Kelsey and company branded Imetelstat failure for solid tumopr application last fall and caused that massive share-price slide!! I wonder if it was a deliberate action and, hence, a fraud or as Stifel's Klein argues the flawed trials plan by the mangement? What was Kelsey upto when he was privy to all the information when Scarlett openly stated the solid-tumor trials had failled? If I were to hold the power to change the company management, I will fire Scarlett, Kelsey and Huh and bring in more dynamic and mature replacement. None of them really is fit to run Geron. Instead of growing the company, they have managed to shrink it to dangerously low level. They have reduced once well-known outfit to one of the lame oncology research outfit. For what reasons?